

Patient Name: J RAVI KUMAR Ref. Doctor: Dr Prakashnagar Patient Id: 0000262616 Lab Id: 02254003733 OP Id: HY-PRA-0225-00264 Sample Collection Date & Time: 27/02/2025 11:43 A

OP Id: HY-PRA-0225-00264 Sample Collection Date & Time: 27/02/2025 11:43 AM Age/Gender: 41 Years/Female Reporting Date & time: 28/02/2025 06:59 AM

HAEMATOLOGY COMPLETE BLOOD PICTURE

Investigation	Result	Normal Reference Range
Specimen:Blood (K2EDTA)		
Total Leukocyte Count (Method: Flowcytometry)	$8.32 \times 10^{3}/\text{uL}$	$4.0\text{-}10.0 \text{ X } 10^3/\text{uL}$
Total Red Blood Cell Count (Method: Hydrodynamic Focussing Method)	$5.50 \text{ X}10^{12}/\text{L}$	$3.8 - 4.8 \times 10^{12}/L$
Hb (Method: SLS - HB)	17.0 g/dL	12.0 - 15.0 g/dL
HCT (Method: Calculated)	47.8 %	36 - 46 %
Mean Corpuscular Volume (MCV) (Method: RBC Histogram)	86.9 fl	83 - 101 fl
Mean Corpuscular Hemoglobin (MCH) (Method: Calculated)	30.9 pg	27 - 32 pg
MCHC (Method: Calculated)	35.5 g/dl	31.5 - 34.5 g/dl
Platelet Count (Method: Hydrodynamic Focussing Method)	160 X 10 ³ /uL	150 - 410 X 10³/uL
DIFFERI	ENTIAL LEUKOCYTE CO	UNT
Neutrophils	62.1 %	2.0-7.5 X 10 ³ /uL (40 - 80%)
Lymphocytes	29.0 %	1.0-4.0 X 10 ³ /uL (20 - 40%)
Monocytes	4.5 %	0.2-1.0 X 10 ³ /uL(2 - 10%)
Eosinophils	3.0 %	0.02-0.5 X 10 ³ /uL (1-6%)
Basophils	1.4 %	0.02 - 0.1 X 10 ³ /uL (1-2%)
Method	Flowcytometry	
Notes	*** END OF REPORT ***	

Test Performed By : nalhub

Loulpin

Consultant Pathologist

OP Id: HY-PRA-0225-00264 Sample Collection Date & Time: 27/02/2025 11:43 AM Age/Gender: 41 Years/Female Reporting Date & time: 27/02/2025 10:52 PM

CLINICAL BIOCHEMISTRY

Investigation	Result	Biological Reference Interval
*		

Specimen: Whole Blood

HbA1c (Method: Immunoturbidimetry) 5.38 %

4 - 6 %

Interpretation : HbA1c is a form of hemoglobin that is measured primarily to identify the three-month average plasma glucose concentration

*** END OF REPORT ***

Please correlate clinically



Ref. Doctor: Patient Name: J RAVI KUMAR Dr Prakashnagar Patient Id: 0000262616 Lab Id: 02254003733

27/02/2025 11:43 AM OP Id: HY-PRA-0225-00264 Sample Collection Date & Time: 41 Years/Female Reporting Date & time: 28/02/2025 10:47 AM Age/Gender:

CLINICAL BIOCHEMISTRY

Investigation **Biological Reference Interval** Result

Specimen:Flouride Plasma

Random Blood Glucose 127 mg/dL (Method: Hexokinase)

74 - 140 mg/dL

C Sowny Layti

Interpretation: Glucose determination is useful in the diagnosis and treatment of Diabetes mellitus. Elevated

levels are found in pancreatitis, pituitary and thyroid dysfunction, renal failure and liver diseases. Low glucose levels are found in insulinoma, hypopituitarism, neoplasms, insulin induced

hypoglycemia

*** END OF REPORT ***

Please correlate clinically



OP Id: HY-PRA-0225-00264 Sample Collection Date & Time: 27/02/2025 11:43 AM Age/Gender: 41 Years/Female Reporting Date & time: 28/02/2025 01:26 PM

CLINICAL BIOCHEMISTRY RENAL FUNCTION TEST

19.09 mg/dL	17 - 43 mg/dL
0.84 mg/dL	0.55 - 1.02 mg/dL
*** END OF REPORT ***	
	C Sowny bydi
	0.84 mg/dL



 OP Id:
 HY-PRA-0225-00264
 Sample Collection Date & Time:
 27/02/2025 11:43 AM

 Age/Gender:
 41 Years/Female
 Reporting Date & time:
 28/02/2025 01:25 PM

CLINICAL BIOCHEMISTRY LIPID PROFILE

Investigation	Result	Biological Reference Interval
Specimen:Serum		
S.Total Cholesterol (Method: CHOD-POD)	216 mg/dL	Desirable Level : <200 mg/dL Borderline : 200 - 239 mg/dL Undesirable : > 240 mg/dL
S.Triglycerides (Method: GPO-POD)	134 mg/dL	Desirable Level : <150 mg/dL Borderline : 150 - 199 mg/dL High : 200 - 499 mg/dL Very High : >500 mg/dL
S.HDL (Method: Enzyme Selective Inhibition)	48.7 mg/dL	Desirable Level : >60 mg/dL Borderline : 40 - 59 mg/dL Undesirable : <40 mg/dL
VLDL (Method: Calculated)	26.81 mg/dL	<30 mg/dL
S.LDL (Method: Calculated)	169 mg/dL	Optimal : <100 mg/dL Near Optimal : 100 - 129 mg/dL Borderline High : 130 - 159 mg/dL High : 160 - 189 mg/dL Very High : >190 mg/dL
T.Chol/HDL (Method: Calculated)	4.44	Low Risk: 3.3-4.4 Average Risk: 4.5-7.1 Moderate Risk: 7.2-11.0
LDL/HDL (Method: Calculated)	3.49	Desirable Level: 0.5-3.0 Borderline Risk: 3.0-6.0 High Risk: >6.0

Interpretation: The results of this test can identify certain genetic diseases and can determine approximate risks for cardiovascular disease, certain forms of pancreatitis, and other diseases

*** END OF REPORT ***

C Sowny- haydi

Please correlate clinically



 OP Id:
 HY-PRA-0225-00264
 Sample Collection Date & Time:
 27/02/2025 11:43 AM

 Age/Gender:
 41 Years/Female
 Reporting Date & time:
 28/02/2025 01:21 PM

CLINICAL BIOCHEMISTRY LIVER FUNCTION TEST

Investigation	Result	Biological Reference Interval
Specimen:Serum		
S. Bilirubin T (Method: DPD)	1.1 mg/dL	0.3 - 1.2 mg/dL
S. Bilirubin D (Method: DPD)	0.3 mg/dL	<0.2 mg/dL
S.Total Protein (Method: Biuret)	7.5 gm/dL	6.6 - 8.3 gm/dL
S.Albumin (Method: BCG)	4.3 gm/dL	3.5 - 5.2 gm/dL
Globulin (Method: Calculated)	3.26 gm/dL	2.6-3.9 gm/dL
A/G Ratio (Method: Calculated)	1.31	1.0 - 1.7
SGOT/AST (Method: UV without P5P)	36 U/L	< 35 U/L
SGPT /ALT (Method: UV without P5P)	36 U/L	< 35 U/L
S.Alkaline Phosphatase (Method: IFCC)	92 U/L	30 - 120 U/L

Interpretation: Liver function tests (LFTs or LFs) are groups of blood tests that give information about the state of a patient's liver. Liver transaminases (AST or SGOT and ALT or SGPT) are useful biomarkers of liver injury in a patient with some degree of intact liver function. Some tests are associated with functionality (e.g., albumin), some with cellular integrity (e.g., transaminase), and some with conditions linked to the biliary tract (gamma-glutamyl transferase and alkaline phosphatase). GGT plays a role in the detection of alcoholism, alcoholic liver damage and in monitoring alcohol abstinence.

*** END OF REPORT ***

C Sowny Layeti

Please correlate clinically

OP Id: HY-PRA-0225-00264 Sample Collection Date & Time: 27/02/2025 11:43 AM Age/Gender: 41 Years/Female Reporting Date & time: 27/02/2025 07:30 PM

CLINICAL BIOCHEMISTRY

Investigation Result Biological Reference Interval

Specimen:Serum

Troponin - I (Rapid)
(Method: Rapid)

Negative

Interpretation Cardiac Troponin I elevates in all patients with acute myocardial infarction (MI). Clinical findings, ECG & other serological findings should be considered for a confirmative diagnosis. The initial

appearance of elevated cTnI in the blood of individuals suffered from AMI is variable; from 3-24 hours depending on factors such as infarct size. Elevated cTnI levels can be measured for up to 14

days in some patients.

*** END OF REPORT ***

Please correlate clinically

27/02/2025 11:43 AM OP Id: HY-PRA-0225-00264 Sample Collection Date & Time: 41 Years/Female Reporting Date & time: 28/02/2025 01:20 PM Age/Gender:

CLINICAL BIOCHEMISTRY

Investigation **Biological Reference Interval** Result

Specimen:Serum

S. Calcium 9.2 mg/dL

8.8 - 10.6 mg/dL (Method: Arsenazo III)

Interpretation Used in diagnosis & monitoring of a wide range of disorders, including disorders of protein & vitamin D & diseases of bone, kidney, parathyroid gland or GI tract. Total protein & albumin should always be measured simultaneously for proper interpretation of serum calcium levels

*** END OF REPORT ***

Please correlate clinically



 OP Id:
 HY-PRA-0225-00264
 Sample Collection Date & Time:
 27/02/2025 11:43 AM

 Age/Gender:
 41 Years/Female
 Reporting Date & time:
 28/02/2025 01:22 PM

CLINICAL BIOCHEMISTRY

Investigation Result Biological Reference Interval

Specimen:Serum

S.Uric Acid (Method: Uricase) 6.2 mg/dL 2.6 - 6.0 mg/dL

*** END OF REPORT ***

Please correlate clinically